Crenolanib is an investigational pharmaceutical compound that functions as a tyrosine kinase inhibitor. It is being studied in clinical trials for various cancer types, including acute myeloid leukemia, gastrointestinal stromal tumor, and glioma.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 670220-88-9
Neratinib
pharmaceutical raw material
Xl-228
pharmaceutical raw material
Wz-4002
pharmaceutical raw material
Repotrectinib
pharmaceutical raw material
(3β)-3-Hydroxyandrost-5-en-17-one-16,16-d2
pharmaceutical raw material
(R)-metirosine
pharmaceutical raw material
Metirosine
pharmaceutical raw material
Dipalmitoyl phosphatidylglycerole sodium salt
pharmaceutical raw material
1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DYNHJHQFHQTFTP-UHFFFAOYSA-N
CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4